Patent SG-11201907232X-A (SG)
Title: 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
Inventor: GUTCHER ILONA
IPC: C07D417/14
Filed: 2018-02-02
Abstract: Filing Language: (26) Publication Language: (30) Priority Data: 17155406.6 17202882.1 02 February 2018 (02.02.2018) English English 09 February 2017 (09.02.2017) EP 21 November 2017 (21.11.2017) EP R 5 W N 0 I .0\" 0 © R . 0 0 2 H N 'IR O O 1-1 O 71- 1-1 3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT omit VIII °nolo olomiloollm Hollow° oimIE (10) International Publication Number WO 2018/146010 Al (51) International Patent Classification: C07D 401/14 (2006.01) C07D 409/04 (2006.01) C07D 405/14 (2006.01) C07D 413/04 (2006.01) C07D 401/04 (2006.01) CO7D 417/04 (2006.01) C07D 403/04 (2006.01) CO7D 417/14 (2006.01) C07D 237/04 (2006.01) A61K 31/501 (2006.01) C07D 237/24 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/052627 (22) International Filing Date: (71) Applicants: BAYER AKTIENGESELLSCHAFT [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Lev- erkusen (DE). BAYER PHARMA AKTIENGESEL- LSCHAFT [DE/DE]; Miillerstr. 178, 13353 Berlin (DE). DEUTSCHES KREBSFORSCHUNGSZEN- TRUM [DE/DE]; Im Neuenheimer Feld 280, 69120 Hei- delberg (DE). (72) Inventors: GUTCHER, Ilona; Paul-Robeson-Str. 28, 10439 Berlin (DE). ROHN, Ulrike; Boyenstr. 42, 10115 Berlin (DE). SCHMEES, Norbert; Bondickstr. 61, 13469 Berlin (DE). ZORN, Ludwig; Osianderweg 45A, 13509 Berlin (DE). ROSE, Lars; Fuchsring 82, 13465 Berlin (DE). BADER, Benjamin; Hillmannstr. 14, 13467 Berlin (DE). KOBER, Christina; Heidelberger Str. 18, 76646 Bruchsal (DE). CARRETERO, Rafael; Milhlingstr. 6, 69121 Heidelberg (DE). STOCKIGT, Detlef; Clara- Zetkin-Str. 27, 14471 Potsdam (DE). IRLBACHER, Horst; Winsstr. 47, 10405 Berlin (DE). PLATTEN, Michael; Cambridgestr. 7, 69115 Heidelberg (DE). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Mon- heim am Rhein (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 (54) Title: 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER (57) : The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carbox- amide compounds of general formula (I), in which X, R1, R 2 , R 3 , R4 and - lc 5 are as defined here- in, methods of preparing said compounds, intermediate compounds useful for preparing said com- pounds, pharmaceutical compositions and combinations comprising said compounds and the use of (I) said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other dis- orders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.